Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience's stock price has experienced significant volatility and a notable decline over the past year. Key events impacting the stock in the past six months include the Q2 2025 earnings report, which exceeded expectations but had a slight decline in gross margin and regional revenue declines. The CEO retired and new appointments were made to the Board of Directors. The company received an extension from Nasdaq to regain compliance with the minimum bid price requirement. The Q3 2025 financial results reported revenue that exceeded expectations but was a year-over-year decline, with EPS missing forecasts but improved profitability metrics.

Specific information detailing the demand seasonality for Harvard Bioscience's products and services was not explicitly found in the provided search results. However, the company's customer base suggests that demand may be influenced by factors such as research funding cycles, academic calendars, and drug discovery and development timelines. The Q3 2025 earnings call noted that Q3 is historically a cyclically soft quarter.

Harvard Bioscience, Inc. is a global developer, manufacturer, and marketer of specialized technologies, products, and services for life science applications, including fundamental research, pharmaceutical and therapy discovery, bioproduction, and preclinical testing for drug development. The company operates within the Healthcare sector and the Medical Instruments & Supplies industry. Its product portfolio includes Cellular and Molecular Technology (CMT) and Preclinical products, as well as contract manufacturing, custom solutions, and services like data analysis, training, and installation. The company markets its products under several brands, including Harvard Apparatus, DSI, Buxco, and Biochrom.

Harvard Bioscience operates globally, serving customers in over 100 countries, with operations in North America, Europe, and China. It sells its products through direct sales organizations, websites, and a network of distributors. The majority of its revenue is generated from the United States. The company has five principal manufacturing facilities located in New Brighton, Minnesota; Holliston, Massachusetts; Reutlingen, Germany; Barcelona, Spain; and March, Germany.

Harvard Bioscience has a long-standing history, founded in 1901, and is considered a trusted name in the life sciences industry. The company is recognized for providing cutting-edge technologies and services that advance life science applications globally. No specific events negatively or positively impacting Harvard Bioscience's brand reputation in the past year were found in the provided search results beyond the general course of business operations and financial performance.

Harvard Bioscience has a mixed ownership structure, with institutional, retail, and individual investors. Approximately 29.52% to 33.36% of the company's stock is owned by Institutional Investors, while insiders own about 10.07%. Major institutional owners include AMH Equity Ltd, Harvey Partners, LLC, and Vanguard Group Inc. James W. Green is a major individual owner.